References
- Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004 Jul-Aug;218(4):223–236. doi:https://doi.org/10.1159/000078612.
- Ten Doesschate J. Causes of blindness in The Netherlands. Doc Ophthalmol. 1982 Jan 29;52(3–4):279–285. doi:https://doi.org/10.1007/BF01675857.
- National Advisory Eye Council (U.S.). Vision Research: A National Plan: 1983-1987. Bethesda, Md.: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health; 1983.
- Pistilli M, Joffe MM, Gangaputra SS, et al. Visual acuity outcome over time in non-infectious uveitis. Ocul Immunol Inflamm. Dec 10 2019: 1–8. doi:https://doi.org/10.1080/09273948.2019.1687733.
- Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology. 1996 Nov;103(11):1846–1853. doi:https://doi.org/10.1016/S0161-6420(96)30417-X.
- Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332–336. doi:https://doi.org/10.1136/bjo.80.4.332.
- Kempen JH, Daniel E, Gangaputra S, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the systemic immunosuppressive therapy for eye diseases (SITE) cohort study. Ophthalmic Epidemiol. Jan-Feb. 2008;15(1):47–55. doi:https://doi.org/10.1080/09286580701585892.
- Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. Bmj. 2009;339:b2480. doi:https://doi.org/10.1136/bmj.b2480.
- Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005 Sep;140(3):509–516.
- Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982 Jul;94(1):91–96. doi:https://doi.org/10.1016/0002-9394(82)90197-0.
- Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004 Sep;88(9):1159–1162. doi:https://doi.org/10.1136/bjo.2003.037226.
- Mehta S, Linton MM, Kempen JH. Outcomes of cataract surgery in patients with uveitis: a systematic review and meta-analysis. Am J Ophthalmol. 2014 Jun 28;158(4):676–692.e7. doi:https://doi.org/10.1016/j.ajo.2014.06.018.
- Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. May. 2011;129(5):545–553. doi:https://doi.org/10.1001/archophthalmol.2010.339.
- Gonzales CA, Ladas JG, Davis JL, Feuer WJ, Holland GN. Relationships between laser flare photometry values and complications of uveitis. Arch Ophthalmol. 2001 Dec;119(12):1763–1769. doi:https://doi.org/10.1001/archopht.119.12.1763.
- Neri P, Lettieri M, Fortuna C, Manoni M, Giovannini A. Inflammatory choroidal neovascularization. Middle East Afr J Ophthalmol. Oct 2009;16(4):245–251.
- Taylor SR, Lightman SL, Sugar EA, et al. The impact of macular edema on visual function in intermediate, posterior, and panuveitis. Ocul Immunol Inflamm. Jun 2012;20(3):171–181. doi:https://doi.org/10.3109/09273948.2012.658467.
- Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006 Aug;113(8):1446–1449. doi:https://doi.org/10.1016/j.ophtha.2006.03.027.
- Schubert HD. Postsurgical hypotony: relationship to fistulization, inflammation, chorioretinal lesions, and the vitreous. Surv Ophthalmol. 1996;41(2):97–125. Sep-Oct. doi:https://doi.org/10.1016/S0039-6257(96)80001-4.
- Daniel E, Pistilli M, Pujari SS, et al. Risk of hypotony in noninfectious uveitis. Ophthalmology. Nov 2012;119(11):2377–2385. doi:https://doi.org/10.1016/j.ophtha.2012.05.032.
- Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. Apr 2004;122(4):477–485.
- Lin P, Loh AR, Margolis TP, Acharya NR. Cigarette smoking as a risk factor for uveitis. Ophthalmology. 2010 Mar;117(3):585–590. doi:https://doi.org/10.1016/j.ophtha.2009.08.011.
- Galor A, Feuer W, Kempen JH, et al. Adverse effects of smoking on patients with ocular inflammation. Br J Ophthalmol. Jul 2010;94(7):848–853. doi:https://doi.org/10.1136/bjo.2009.174466.
- Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA, Multicenter Uveitis Steroid Treatment Trial Research G. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010 Apr;149(4):550–561 e510.
- Khairallah M, Accorinti M, Muccioli C, Kahloun R, Kempen JH. Epidemiology of Behcet disease. Ocul Immunol Inflamm. 2012 Oct;20(5):324–335. doi:https://doi.org/10.3109/09273948.2012.723112.
- Multicenter Uveitis Steroid Treatment Trial Research G, Kempen JH, Altaweel MM, Lea TD. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Ophthalmology. 2015 Oct;122(10):1967–1975.